KCTD5

KCTD5 is a pentameric BTB-domain protein that serves as a substrate-specific adaptor for Cullin3-based E3 ubiquitin ligase complexes, with its best-characterized role being the ubiquitin-dependent degradation of free Gβγ subunits to restrain GPCR/cAMP signaling. Its C-terminal domain symmetrically engages five Gβγ copies while its BTB domain recruits CUL3, forming a CRL3–ARIH1 E3-E3 superassembly that positions ubiquitin transfer onto Gβ Lys-23; conditional Kctd5 knockout in striatal neurons causes augmented dopamine-evoked cAMP signaling and a dystonic motor phenotype rescued by a Gβγ-scavenging nanobody (PMID:37450587, PMID:38625940, PMID:40233107). Beyond Gβγ, the CUL3/KCTD5 complex polyubiquitinates RhoGDI1 for degradation and monoubiquitinates ΔNp63α to impair its transcriptional activity, while KCTD5 also stabilizes Ikaros transcription factor isoforms through direct interaction, indicating substrate-dependent outcomes ranging from degradation to stabilization (PMID:32876072, PMID:29782646, PMID:38424700). Homozygous Kctd5 knockout is embryonic lethal in mice, and heterozygous loss causes dyslipidemia with elevated cholesterol and triglycerides, implicating KCTD5 in lipid metabolic homeostasis (PMID:40846050).

1. 2008 High

   Establishing KCTD5 as a Cullin3 adaptor resolved its molecular identity: the BTB domain plus flanking residues bind CUL3, and KCTD5 oligomerizes and associates with ubiquitinated proteins, framing it as a substrate receptor for CRL3 complexes.

   Evidence Co-immunoprecipitation with N-terminal deletion mutagenesis and subcellular fractionation in cultured cells

   PMID:18573101

   Open questions at the time

   • No physiological substrate was identified
   • Oligomeric stoichiometry was not determined
   • No in vivo functional consequence of CUL3 interaction was tested
2. 2015 Medium

   Identification of MCM7, ZNF711, and FAM193B as KCTD5/CUL3-interacting proteins expanded the potential substrate repertoire but revealed an unexpected stabilization function for ZNF711, complicating a simple degradation model.

   Evidence Yeast two-hybrid and co-immunoprecipitation with protein stability assays in mammalian cells

   PMID:26188516

   Open questions at the time

   • Stabilization mechanism is unexplained and not independently replicated
   • Whether these partners are bona fide ubiquitination substrates remains unresolved
3. 2018 Medium

   Demonstrating that CUL3/KCTD5 monoubiquitinates ΔNp63α—impairing its DNA binding, transactivation, and pro-proliferative function—established the first substrate with a defined functional outcome and showed KCTD5 can modulate transcription factor activity without promoting degradation.

   Evidence Co-immunoprecipitation, in vivo ubiquitination assay, EMSA, reporter and proliferation assays

   PMID:29782646

   Open questions at the time

   • Not independently replicated
   • In vivo relevance of ΔNp63α regulation by KCTD5 is untested
   • The ubiquitin chain type or modification site on ΔNp63α was not mapped
4. 2020 Medium

   Identification of RhoGDI1 as a CUL3/KCTD5 degradation substrate, together with cell migration and Rac1/Ca²⁺ signaling phenotypes upon KCTD5 loss, connected the ligase to cytoskeletal regulation and focal adhesion dynamics.

   Evidence Co-IP and ubiquitination assays for RhoGDI1 degradation; CRISPR/shRNA knockdown with live-cell focal adhesion imaging, dominant-negative Rac1, Ca²⁺ imaging, and ionomycin rescue in B16-F10 cells

   PMID:32876072 PMID:33053687

   Open questions at the time

   • Whether RhoGDI1 degradation directly causes the migration phenotype was not tested
   • Migration phenotype studied only in melanoma cells; generalizability unknown
   • Ubiquitination site(s) on RhoGDI1 not mapped
5. 2023 High

   Cryo-EM resolution of the pentameric KCTD5–Gβγ architecture demonstrated that five C-terminal domains symmetrically capture five Gβγ copies for simultaneous CRL3-mediated ubiquitination, establishing Gβγ as a major physiological substrate and linking KCTD5 to GPCR/cAMP signal attenuation.

   Evidence Cryo-EM structure of KCTD5–Gβγ fusion complex; cAMP signaling assays

   PMID:37450587

   Open questions at the time

   • Structure used a fusion construct; native complex architecture awaited confirmation
   • In vivo neuronal relevance was not yet shown
6. 2023 Medium

   Discovery that KCTD5 forms hetero-oligomeric complexes with other KCTD family members (KCTD2, KCTD17) via distinct regions raised the possibility of combinatorial substrate recognition or regulation among KCTD paralogs.

   Evidence Co-immunoprecipitation, live-cell BRET, and domain-mapping luminescence assays

   PMID:37762619

   Open questions at the time

   • Functional consequence of hetero-oligomerization is unknown
   • Stoichiometry of heteromeric assemblies not determined
   • Not independently confirmed
7. 2024 High

   Structural and biochemical characterization of the full CRL3KCTD5–ARIH1 E3-E3 superassembly showed how >60° rotational dynamics between BTB/CUL3 and CTD/Gβγ moieties position ARIH1~ubiquitin for priming ubiquitination at Gβ Lys-23, providing the catalytic mechanism for substrate ubiquitylation.

   Evidence Cryo-EM of pentameric KCTD5/CUL3NTD/Gβ1γ2 complex; BRET interaction assays; in vitro ubiquitylation assays

   PMID:38625940

   Open questions at the time

   • Whether ARIH1 involvement generalizes to other KCTD5 substrates (RhoGDI1, ΔNp63α) is unknown
   • Dynamics were inferred from conformational heterogeneity in cryo-EM; real-time kinetics not measured
8. 2024 Medium

   Identification of Ikaros transcription factor isoforms as KCTD5-stabilized interactors—whose association is disrupted by etoposide—expanded KCTD5 function beyond ubiquitin-mediated degradation to include context-dependent protein stabilization in leukemic cells.

   Evidence IP-LC-MS/MS proteomics, co-immunoprecipitation, protein stability and siRNA knockdown assays in leukemic cells

   PMID:38424700

   Open questions at the time

   • Mechanism of stabilization (e.g., whether CUL3 is involved) is unknown
   • Not independently replicated
   • In vivo relevance in leukemia untested
9. 2025 High

   Conditional Kctd5 knockout in striatal neurons produced dystonia and augmented dopamine-evoked cAMP, rescued by a Gβγ-scavenging nanobody, providing the first in vivo proof that KCTD5 functions as a physiological brake on Gβγ/cAMP signaling in the basal ganglia.

   Evidence Conditional KO mouse, 2-photon cAMP biosensor imaging, Gβγ-scavenging nanobody and pharmacological rescue, behavioral assays

   PMID:40233107

   Open questions at the time

   • Whether the dystonic phenotype reflects striatal-specific or broader CNS KCTD5 function is unclear
   • Contribution of non-Gβγ substrates to the neuronal phenotype was not dissected
10. 2025 Medium

    Demonstrating that homozygous Kctd5 knockout is embryonic lethal and heterozygotes show dyslipidemia with elevated cholesterol/triglycerides revealed an essential developmental role and an unanticipated function in lipid homeostasis.

    Evidence CRISPR/Cas9 global Kctd5 KO mice, metabolic phenotyping, genome-wide expression analysis

    PMID:40846050

    Open questions at the time

    • The lipid phenotype link to PPAR signaling is correlative; direct KCTD5 substrates in lipid metabolism are unidentified
    • Cause of embryonic lethality not determined
    • Whether the dyslipidemia is Gβγ-dependent or reflects a distinct substrate axis is unknown

• A major unresolved question is how KCTD5 selects among its diverse substrates (Gβγ, RhoGDI1, ΔNp63α, Ikaros) and determines whether a given interaction leads to degradative ubiquitination, non-degradative ubiquitination, or protein stabilization.
• No unified substrate-selection model exists
• Role of KCTD hetero-oligomerization in substrate specificity is unexplored
• Tissue-specific substrate hierarchy in vivo is undefined